Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2015 | Pages:
172 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2015', provides an overview of the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Overview 10 Therapeutics Development 11 Pipeline Products for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Overview 11 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics under Development by Companies 12 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Unknown Stage Products 17 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Products under Development by Companies 18 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Companies Involved in Therapeutics Development 21 Alvogen Korea 21 AnGes MG, Inc. 22 AstraZeneca Plc 23 Athersys, Inc. 24 Bayer AG 25 Betagenon AB 26 Cardiolynx AG 27 CardioVascular BioTherapeutics, Inc. 28 Celgene Corporation 29 Diffusion Pharmaceuticals LLC 30 DNAVEC Corporation 31 Hemostemix Ltd 32 Mesoblast Limited 33 miRagen Therapeutics, Inc. 34 Multi Gene Vascular Systems Ltd 35 Nuo Therapeutics, Inc. 36 Proteon Therapeutics, Inc. 37 Recardio GmbH 38 Resverlogix Corp. 39 Sagene Pharmaceuticals, Inc. 40 Stemedica Cell Technologies, Inc. 41 Symic Biomedical, Inc. 42 Theravasc, Inc. 43 ViroMed Co., Ltd. 44 Yuyu Pharma, Inc. 45 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics Assessment 46 Assessment by Monotherapy Products 46 Assessment by Combination Products 47 Assessment by Target 48 Assessment by Mechanism of Action 50 Assessment by Route of Administration 52 Assessment by Molecule Type 54 Drug Profiles 56 (cilostazol + organic nitrate) ER - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 ACP-01 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 AEM-28 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 ALD-301 - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 Annexin A-5 - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 apabetalone - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 beperminogene perplasmid - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 CVBT-141C - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 DVC1-0101 - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 ELS-140 - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 Gene Therapy for Critical Limb Ischemia and Peripheral Arterial Disease - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 MGN-6114 - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 MultiGeneAngio - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 MultiStem - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 O-304 - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 PDA-002 - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 REC-03 - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 Rejuveinix - Drug Profile 88 Product Description 88 Mechanism of Action 88 R&D Progress 88 rivaroxaban - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 sarpogrelate SR - Drug Profile 95 Product Description 95 Mechanism of Action 95 R&D Progress 95 SB-030 - Drug Profile 96 Product Description 96 Mechanism of Action 96 R&D Progress 96 selegiline + Antiplatelet Drugs - Drug Profile 97 Product Description 97 Mechanism of Action 97 R&D Progress 97 sodium nitrite SR - Drug Profile 98 Product Description 98 Mechanism of Action 98 R&D Progress 98 Stem Cell Therapy for Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease, Infectious Disease and Toxicology - Drug Profile 100 Product Description 100 Mechanism of Action 100 R&D Progress 100 Synthetic Peptide to Inhibit PAI-1 for Cardiovascular Diseases and Oncology - Drug Profile 102 Product Description 102 Mechanism of Action 102 R&D Progress 102 ticagrelor - Drug Profile 103 Product Description 103 Mechanism of Action 103 R&D Progress 103 transcrocetinate sodium - Drug Profile 107 Product Description 107 Mechanism of Action 107 R&D Progress 107 TXA-127 - Drug Profile 108 Product Description 108 Mechanism of Action 108 R&D Progress 108 VM-202 - Drug Profile 110 Product Description 110 Mechanism of Action 110 R&D Progress 110 vonapanitase - Drug Profile 112 Product Description 112 Mechanism of Action 112 R&D Progress 112 YY-984 - Drug Profile 114 Product Description 114 Mechanism of Action 114 R&D Progress 114 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Recent Pipeline Updates 115 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects 160 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Discontinued Products 162 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Product Development Milestones 163 Featured News & Press Releases 163 Oct 12, 2015: Proteon Therapeutics Announces Results from Phase 1 Study of Investigational Drug Vonapanitase in Patients with Symptomatic Peripheral Artery Disease Presented at TCT 2015 163 Aug 13, 2015: Proteon Therapeutics Announces Top-Line Results From Phase 1 Study of Investigational Drug Vonapanitase in Patients With Symptomatic Peripheral Artery Disease 163 Feb 02, 2015: The Small molecule AMPK activator O304 acts as an oral PCSK9 inhibitor 164 Jan 08, 2015: Journal of Cardiovascular Pharmacology Publishes Positive Nonclinical Results of Proteon Therapeutics' PRT-201 in Peripheral Artery Disease 165 Sep 02, 2014: Capstone Therapeutics Announces Phase 1a Results for AEM-28 Showing Safety and Biomarker Efficacy Signals 165 Mar 17, 2014: AstraZeneca Announces Progress on Global PARTHENON Clinical Trial Program with BRILINTA in High-Risk Cardiovascular Disease Patient Populations in Advance of American College of Cardiology Scientific Session 166 Mar 05, 2013: Tarix Pharma's Peptide Technology Stimulates Revascularization Following Ischemia 168 Dec 06, 2012: Cytomedix Announces Landmark Bright Cell Therapy Study In Peripheral Arterial Disease 169 Oct 15, 2012: Proteon Therapeutics Initiates Patient Enrollment In Phase I Clinical Study Of PRT-201 In Patients Suffering From Peripheral Artery Disease 170 Aug 17, 2012: Anges Announces Publication of Long-Term Phase I/II Trial Data of Collategene In Medical Journal 170 Appendix 171 Methodology 171 Coverage 171 Secondary Research 171 Primary Research 171 Expert Panel Validation 171 Contact Us 171 Disclaimer 172
List of Tables
Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), H2 2015 11 Number of Products under Development by Companies, H2 2015 13 Comparative Analysis by Late Stage Development, H2 2015 14 Comparative Analysis by Clinical Stage Development, H2 2015 15 Comparative Analysis by Early Stage Development, H2 2015 16 Comparative Analysis by Unknown Stage Development, H2 2015 17 Products under Development by Companies, H2 2015 18 Products under Development by Companies, H2 2015 (Contd..1) 19 Products under Development by Companies, H2 2015 (Contd..2) 20 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Alvogen Korea, H2 2015 21 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by AnGes MG, Inc., H2 2015 22 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by AstraZeneca Plc, H2 2015 23 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Athersys, Inc., H2 2015 24 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Bayer AG, H2 2015 25 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Betagenon AB, H2 2015 26 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Cardiolynx AG, H2 2015 27 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by CardioVascular BioTherapeutics, Inc., H2 2015 28 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Celgene Corporation, H2 2015 29 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Diffusion Pharmaceuticals LLC, H2 2015 30 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by DNAVEC Corporation, H2 2015 31 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Hemostemix Ltd, H2 2015 32 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Mesoblast Limited, H2 2015 33 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by miRagen Therapeutics, Inc., H2 2015 34 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Multi Gene Vascular Systems Ltd, H2 2015 35 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Nuo Therapeutics, Inc., H2 2015 36 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Proteon Therapeutics, Inc., H2 2015 37 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Recardio GmbH, H2 2015 38 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Resverlogix Corp., H2 2015 39 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Sagene Pharmaceuticals, Inc., H2 2015 40 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Stemedica Cell Technologies, Inc., H2 2015 41 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Symic Biomedical, Inc., H2 2015 42 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Theravasc, Inc., H2 2015 43 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by ViroMed Co., Ltd., H2 2015 44 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Yuyu Pharma, Inc., H2 2015 45 Assessment by Monotherapy Products, H2 2015 46 Assessment by Combination Products, H2 2015 47 Number of Products by Stage and Target, H2 2015 49 Number of Products by Stage and Mechanism of Action, H2 2015 51 Number of Products by Stage and Route of Administration, H2 2015 53 Number of Products by Stage and Molecule Type, H2 2015 55 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutics - Recent Pipeline Updates, H2 2015 115 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects, H2 2015 160 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects (Contd..1), H2 2015 161 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Discontinued Products, H2 2015 162
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
